The Drug Eluting Stents Center

Filter Your Results

 

News

 

Combining a Drug-Coated Balloon and a Bare-Metal Stent: The REsponse Adapted Combination Therapy (REACT) Strategy

Koen Deloose, MD, and B. Patrice Mwipatayi, MD, MMed, MClinEd, FCS, FRACS

September 2018—Allowing vessel response to guide appropriate treatment for SFA disease.

Assessing the Economic Impact of Peripheral Interventions

Yann Gouëffic, MD, PhD; and Valéry-Pierre Riche

September 2018—The difficulties in weighing cost-effectiveness in treatment algorithms remain.

The Importance of Vessel Preparation

Ralf Langhoff, MD

September 2018—Properly preparing lesions before use of drug-eluting technologies has become a crucial step of the treatment algorithm.

Boston Scientific's Eluvia Peripheral Drug-Eluting Stent Gains FDA Approval

September 24, 2018 -- Boston Scientific has announced US FDA approval of its Eluvia drug-eluting vascular stent system for use in peripheral artery disease. Earlier this …

Cook Medical Gains FDA Approval for 5-mm Zilver PTX Drug-Eluting Stent Diameter

September 24, 2018 -- Cook Medical announced the FDA approval of a 5-mm diameter version of the Zilver PTX paclitaxel-eluting peripheral stent. Zilver PTX is now available wit…

Boston Scientific's Eluvia DES Evaluated for Femoropopliteal Lesions in IMPERIAL Trial

September 22, 2018 -- Boston Scientific announced 12-month data from the IMPERIAL trial evaluating the company's Eluvia paclitaxel-eluting vascular stent system versus the…

Bioresorbable Stent Technology for Femoropopliteal Disease Treatment: Where Do We Stand?

Sabine Steiner, MD; Andrej Schmidt, MD; and Dierk Scheinert, MD

September 2018—Appraising the current literature on bioresorbable technology use in the SFA, what can be learned from the coronary experience, and the future of bioresorbable stents in this anatomy.

Pivotal Trial Begins for Boston Scientific's Saval BTK DES to Treat CLI

September 6, 2018 -- Boston Scientific Corporation announced that it has enrolled the first patient in the SAVAL pivotal trial to evaluate clinical outcomes of the company'…

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.